Ascentage Competitors
| AAPG Stock | 23.61 0.91 3.71% |
Ascentage Pharma vs Soleno Therapeutics Correlation
Poor diversification
The correlation between Ascentage Pharma Group and SLNO is 0.63 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Ascentage Pharma Group and SLNO in the same portfolio, assuming nothing else is changed.
Moving together with Ascentage Stock
Moving against Ascentage Stock
| 0.83 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.75 | DSGN | Design Therapeutics | PairCorr |
| 0.72 | ENGN | enGene Holdings Common | PairCorr |
| 0.56 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.47 | 63E | ONWARD MEDICAL BV | PairCorr |
Ascentage Pharma Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Ascentage Pharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Ascentage and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Ascentage Pharma does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Ascentage Stock performing well and Ascentage Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ascentage Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CNTA | 2.26 | 0.01 | (0.02) | 0.11 | 2.74 | 4.97 | 26.54 | |||
| APGE | 2.09 | 0.15 | 0.05 | 0.21 | 2.82 | 4.56 | 23.21 | |||
| CELC | 2.25 | 0.57 | 0.24 | 1.07 | 2.00 | 5.87 | 17.89 | |||
| XENE | 1.62 | 0.11 | 0.02 | 0.40 | 1.76 | 3.78 | 10.56 | |||
| CGON | 2.95 | 0.42 | 0.14 | 0.60 | 2.52 | 5.15 | 34.61 | |||
| ZLAB | 1.94 | (0.55) | 0.00 | (0.76) | 0.00 | 4.75 | 10.32 | |||
| LEGN | 2.34 | (0.90) | 0.00 | (16.49) | 0.00 | 3.83 | 19.65 | |||
| RARE | 3.02 | (0.37) | 0.00 | (0.13) | 0.00 | 7.73 | 51.23 | |||
| IRON | 2.16 | (0.22) | 0.00 | (0.86) | 0.00 | 4.33 | 14.87 | |||
| SLNO | 3.12 | (0.66) | 0.00 | (0.50) | 0.00 | 5.40 | 26.59 |
Cross Equities Net Income Analysis
Compare Ascentage Pharma and related stocks such as Centessa Pharmaceuticals, Apogee Therapeutics, and Celcuity LLC Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTA | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (10.7 M) | (381.9 M) | (216.2 M) | (151.1 M) | (235.8 M) | (212.2 M) | (222.8 M) |
| APGE | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (84 M) | (182.1 M) | (163.9 M) | (155.7 M) |
| CELC | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (3.3 M) | (6.3 M) | (7.5 M) | (7.4 M) | (9.5 M) | (29.6 M) | (40.4 M) | (63.8 M) | (111.8 M) | (100.6 M) | (95.6 M) |
| XENE | (12 M) | (12 M) | (4.3 M) | 12 M | 13 M | (15.8 M) | (23 M) | (30.7 M) | (34.5 M) | (41.6 M) | (28.8 M) | (78.9 M) | (125.4 M) | (182.4 M) | (234.3 M) | (210.9 M) | (200.4 M) |
| CGON | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (35.4 M) | (48.6 M) | (88 M) | (79.2 M) | (75.3 M) |
| ZLAB | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (37.5 M) | (50.4 M) | (139.1 M) | (183.4 M) | (268.9 M) | (704.5 M) | (443.3 M) | (334.6 M) | (257.1 M) | (231.4 M) | (243 M) |
| LEGN | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | 9.4 M | (2.8 M) | (101.6 M) | (266.4 M) | (403.6 M) | (446.3 M) | (518.3 M) | (177 M) | (159.3 M) | (167.3 M) |
| RARE | (6.8 M) | (6.8 M) | (16.3 M) | (35.1 M) | (59.8 M) | (145.6 M) | (245.9 M) | (302.1 M) | (197.6 M) | (402.7 M) | (186.6 M) | (454 M) | (707.4 M) | (606.6 M) | (569.2 M) | (512.3 M) | (486.7 M) |
| IRON | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (36 M) | (46.1 M) | (76.4 M) | (109.4 M) | (98.4 M) | (103.3 M) |
| SLNO | (6.5 M) | (6.5 M) | (6.5 M) | (3.7 M) | (13.9 M) | (15.9 M) | (12.1 M) | (15.7 M) | (13.3 M) | (30.8 M) | (24.6 M) | (30.9 M) | (24.1 M) | (39 M) | (175.8 M) | (158.3 M) | (150.4 M) |
Ascentage Pharma and related stocks such as Centessa Pharmaceuticals, Apogee Therapeutics, and Celcuity LLC Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Ascentage Pharma financial statement analysis. It represents the amount of money remaining after all of Ascentage Pharma Group operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Ascentage Pharma Competitive Analysis
The better you understand Ascentage Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Ascentage Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Ascentage Pharma's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Ascentage Pharma Competition Performance Charts
Five steps to successful analysis of Ascentage Pharma Competition
Ascentage Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Ascentage Pharma in relation to its competition. Ascentage Pharma's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Ascentage Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Ascentage Pharma's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Ascentage Pharma, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Ascentage Pharma position
In addition to having Ascentage Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Target Risk ETFs Thematic Idea Now
Target Risk ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Risk ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Risk ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Ascentage Pharma Correlation with its peers. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Can Biotechnology industry sustain growth momentum? Does Ascentage have expansion opportunities? Factors like these will boost the valuation of Ascentage Pharma. If investors know Ascentage will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Ascentage Pharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (2.09) | Revenue Per Share | Quarterly Revenue Growth (0.72) | Return On Assets | Return On Equity |
The market value of Ascentage Pharma is measured differently than its book value, which is the value of Ascentage that is recorded on the company's balance sheet. Investors also form their own opinion of Ascentage Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascentage Pharma's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Ascentage Pharma's market value can be influenced by many factors that don't directly affect Ascentage Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Ascentage Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascentage Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Ascentage Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.